Literature DB >> 24803577

The microenvironment matters: estrogen deficiency fuels cancer bone metastases.

Laura E Wright1, Theresa A Guise2.   

Abstract

Factors released during osteoclastic bone resorption enhance disseminated breast cancer cell progression by stimulating invasiveness, growth, and a bone-resorptive phenotype in cancer cells. Postmenopausal bone loss may accelerate progression of breast cancer growth in bone, explaining the anticancer benefit of the bone-specific antiresorptive agent zoledronic acid in the postmenopausal setting. Clin Cancer Res; 20(11); 2817-9. ©2014 AACR. ©2014 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24803577      PMCID： PMC4061908          DOI： 10.1158/1078-0432.CCR-14-0576

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

Authors:  Michael Gnant; Brigitte Mlineritsch; Herbert Stoeger; Gero Luschin-Ebengreuth; Dietmar Heck; Christian Menzel; Raimund Jakesz; Michael Seifert; Michael Hubalek; Gunda Pristauz; Thomas Bauernhofer; Holger Eidtmann; Wolfgang Eiermann; Guenther Steger; Werner Kwasny; Peter Dubsky; Gerhard Hochreiner; Ernst-Pius Forsthuber; Christian Fesl; Richard Greil
Journal:  Lancet Oncol       Date:  2011-06-05       Impact factor: 41.316

Review 2.  Bone turnover across the menopause transition : The role of gonadal inhibins.

Authors:  Kristy M Nicks; Tristan W Fowler; Nisreen S Akel; Daniel S Perrien; Larry J Suva; Dana Gaddy
Journal:  Ann N Y Acad Sci       Date:  2010-03       Impact factor: 5.691

3.  Bone turnover mediates preferential localization of prostate cancer in the skeleton.

Authors:  Abraham Schneider; Linda M Kalikin; Ana C Mattos; Evan T Keller; Matthew J Allen; Kenneth J Pienta; Laurie K McCauley
Journal:  Endocrinology       Date:  2005-01-06       Impact factor: 4.736

Review 4.  Cancer to bone: a fatal attraction.

Authors:  Katherine N Weilbaecher; Theresa A Guise; Laurie K McCauley
Journal:  Nat Rev Cancer       Date:  2011-05-19       Impact factor: 60.716

5.  Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

Authors:  Penelope D Ottewell; Hannu Mönkkönen; Mark Jones; Diane V Lefley; Robert E Coleman; Ingunn Holen
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

6.  Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.

Authors:  R Coleman; R de Boer; H Eidtmann; A Llombart; N Davidson; P Neven; G von Minckwitz; H P Sleeboom; J Forbes; C Barrios; A Frassoldati; I Campbell; O Paija; N Martin; A Modi; N Bundred
Journal:  Ann Oncol       Date:  2012-10-09       Impact factor: 32.976

Review 7.  Sex steroids and the construction and conservation of the adult skeleton.

Authors:  B Lawrence Riggs; Sundeep Khosla; L Joseph Melton
Journal:  Endocr Rev       Date:  2002-06       Impact factor: 19.871

8.  Breast-cancer adjuvant therapy with zoledronic acid.

Authors:  Robert E Coleman; Helen Marshall; David Cameron; David Dodwell; Roger Burkinshaw; Maccon Keane; Miguel Gil; Stephen J Houston; Robert J Grieve; Peter J Barrett-Lee; Diana Ritchie; Julia Pugh; Claire Gaunt; Una Rea; Jennifer Peterson; Claire Davies; Victoria Hiley; Walter Gregory; Richard Bell
Journal:  N Engl J Med       Date:  2011-09-25       Impact factor: 91.245

9.  Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo.

Authors:  Penelope D Ottewell; Ning Wang; Hannah K Brown; Kimberly J Reeves; C Anne Fowles; Peter I Croucher; Colby L Eaton; Ingunn Holen
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

10.  The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.

Authors:  S P Jagdev; R E Coleman; C M Shipman; A Rostami-H; P I Croucher
Journal:  Br J Cancer       Date:  2001-04-20       Impact factor: 7.640
View more
  11 in total

Review 1.  Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer.

Authors:  Tariq Chukir; Yi Liu; Azeez Farooki
Journal:  Br J Clin Pharmacol       Date:  2019-01-25       Impact factor: 4.335

Review 2.  Adjuvant Endocrine Therapy and Bone Health in Breast Cancer.

Authors:  Gregory A Clines; Palak Choksi; Catherine Van Poznak
Journal:  Curr Osteoporos Rep       Date:  2015-10       Impact factor: 5.096

Review 3.  Regulatory Role of the Adipose Microenvironment on Ovarian Cancer Progression.

Authors:  Hussein Chehade; Roslyn Tedja; Harry Ramos; Tejeshwar Singh Bawa; Nicholas Adzibolosu; Radhika Gogoi; Gil Mor; Ayesha B Alvero
Journal:  Cancers (Basel)       Date:  2022-05-01       Impact factor: 6.575

Review 4.  Effects of Estrogens on Osteoimmunology: A Role in Bone Metastasis.

Authors:  Julien C Marie; Edith Bonnelye
Journal:  Front Immunol       Date:  2022-05-23       Impact factor: 8.786

5.  Single-Limb Irradiation Induces Local and Systemic Bone Loss in a Murine Model.

Authors:  Laura E Wright; Jeroen T Buijs; Hun-Soo Kim; Laura E Coats; Anne M Scheidler; Sutha K John; Yun She; Sreemala Murthy; Ning Ma; Helen J Chin-Sinex; Teresita M Bellido; Ted A Bateman; Marc S Mendonca; Khalid S Mohammad; Theresa A Guise
Journal:  J Bone Miner Res       Date:  2015-06-08       Impact factor: 6.741

6.  Next-Generation Endocrine Therapies for Breast Cancer.

Authors:  Donald P McDonnell; Suzanne E Wardell; Ching-Yi Chang; John D Norris
Journal:  J Clin Oncol       Date:  2021-03-11       Impact factor: 44.544

7.  Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.

Authors:  Laura E Wright; Ahmed A Harhash; Wende M Kozlow; David L Waning; Jenna N Regan; Yun She; Sutha K John; Sreemala Murthy; Maryla Niewolna; Andrew R Marks; Khalid S Mohammad; Theresa A Guise
Journal:  Oncotarget       Date:  2017-01-31

8.  Retrospective study on the efficacy of bisphosphonates in tyrosine kinase inhibitor-treated patients with non-small cell lung cancer exhibiting bone metastasis.

Authors:  Xiaoxian Cui; Shaoli Li; Jincui Gu; Ziying Lin; Bipeng Lai; Lixia Huang; Jinlun Feng; Baomo Liu; Yanbin Zhou
Journal:  Oncol Lett       Date:  2019-09-16       Impact factor: 2.967

9.  Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer.

Authors:  Rui-Min Ma; Chuan-Zhi Chen; Wei Zhang; Jie You; Du-Ping Huang; Gui-Long Guo
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

10.  Effect of sex in the MRMT-1 model of cancer-induced bone pain.

Authors:  Sarah Falk; Tamara Al-Dihaissy; Laura Mezzanotte; Anne-Marie Heegaard
Journal:  F1000Res       Date:  2015-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.